A recent review of more than 10 years of published clinical data revealed that the use of what type of therapy in regimens for gastroenteropancreatic neuroendocrine tumors (GEPNETs) could improve outcomes, minimize toxicity, and reduce the long-term risk of myelodysplastic syndrome and acute leukemia?
- somatostatin analogs therapy
- peptide receptor radionuclide therapy
- cytotoxic drugs
- angiogenesis inhibitors
-----
To see the correct answer, read more.
